查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1420988

認知障礙治療市場（藥物類型：膽鹼酯酶抑制劑和 NMDA 拮抗劑及組合藥物）- 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Cognitive Disorders Treatment Market (Drug Type: Cholinesterase Inhibitors and NMDA Antagonists & Combination Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 162 Pages | 商品交期: 2-10個工作天內

價格

認知障礙治療市場 - 報告範圍

TMR 關於全球認知障礙治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球認知障礙治療的收入2017- 2031年期間的市場，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球認知障礙治療市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解認知障礙治療市場。

市場概況
2023年市場價值 55 億美元
2031 年市場價值 86 億美元
CAGR 5.2%

該報告深入研究了全球認知障礙治療市場的競爭格局。全球認知障礙治療市場的主要參與者已經確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球認知障礙治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 全球主要國家的疾病盛行率和發生率
  • 管道分析
  • 關鍵產業事件（合併、收購、合作關係、合作等）
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依指標分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依指標分類，2017-2031
    • 路易氏體失智症
    • 帕金森氏症 失智症
    • 阿茲海默氏症
    • 血管性失智症
    • 其他適應症
  • 市場吸引力分析：依指標分類

第 7 章：全球市場分析與預測：按藥物類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按藥物類型，2017-2031
    • 膽鹼酯酶抑制劑
    • NMDA 拮抗劑與組合藥物
  • 市場吸引力分析：按藥品類型

第 8 章：全球市場分析與預測：按配銷通路

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2017-2031
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 市場吸引力分析：按配銷通路

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Eisai Co., Ltd.
    • Novartis AG (Knight Therapeutics)
    • Biogen, Inc.
    • Takeda Pharmaceutical Company Limited
    • Dr. Reddy's Laboratories Ltd.
    • Adamas Pharmaceuticals, Inc.
    • Allergan plc
    • Actavis plc
    • H. Lundbeck A/S
Product Code: TMRGL66980

Cognitive Disorders Treatment Market - Scope of Report

TMR's report on the global cognitive disorders treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cognitive disorders treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cognitive disorders treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cognitive disorders treatment market.

Market Snapshot
Market Value in 2023US$ 5.5 Bn
Market Value in 2031US$ 8.6 Bn
CAGR5.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cognitive disorders treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cognitive disorders treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cognitive disorders treatment market.

The report delves into the competitive landscape of the global cognitive disorders treatment market. Key players operating in the global cognitive disorders treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cognitive disorders treatment market profiled in this report.

Key Questions Answered in Global cognitive disorders treatment Market Report:

  • What is the sales/revenue generated by cognitive disorders treatment across all regions during the forecast period?
  • What are the opportunities in the global cognitive disorders treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cognitive Disorders Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global cognitive disorders treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cognitive disorders treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cognitive disorders treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cognitive Disorders Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cognitive Disorders Treatment Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Pipeline Analysis
  • 5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Indication

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Indication, 2017-2031
    • 6.3.1. Lewy Body Dementia
    • 6.3.2. Parkinson's Disease Dementia
    • 6.3.3. Alzheimer's Disease
    • 6.3.4. Vascular Dementia
    • 6.3.5. Other indications
  • 6.4. Market Attractiveness Analysis, By Indication

7. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Drug Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Drug Type, 2017-2031
    • 7.3.1. Cholinesterase Inhibitors
    • 7.3.2. NMDA Antagonists & Combination Drugs
  • 7.4. Market Attractiveness Analysis, By Drug Type

8. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, By Distribution Channel

9. Global Cognitive Disorders Treatment Market Analysis and Forecast, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, By Region

10. North America Cognitive Disorders Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Indication, 2017-2031
    • 10.2.1. Lewy Body Dementia
    • 10.2.2. Parkinson's Disease Dementia
    • 10.2.3. Alzheimer's Disease
    • 10.2.4. Vascular Dementia
    • 10.2.5. Other Indications
  • 10.3. Market Value Forecast, by Drug Type, 2017-2031
    • 10.3.1. Cholinesterase Inhibitors
    • 10.3.2. NMDA Antagonists & Combination Drugs
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Indication
    • 10.6.2. By Drug Type
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Cognitive Disorders Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Indication, 2017-2031
    • 11.2.1. Lewy Body Dementia
    • 11.2.2. Parkinson's Disease Dementia
    • 11.2.3. Alzheimer's Disease
    • 11.2.4. Vascular Dementia
    • 11.2.5. Other Indications
  • 11.3. Market Value Forecast, by Drug Type, 2017-2031
    • 11.3.1. Cholinesterase Inhibitors
    • 11.3.2. NMDA Antagonists & Combination Drugs
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Indication
    • 11.6.2. By Drug Type
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Cognitive Disorders Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Indication, 2017-2031
    • 12.2.1. Lewy Body Dementia
    • 12.2.2. Parkinson's Disease Dementia
    • 12.2.3. Alzheimer's Disease
    • 12.2.4. Vascular Dementia
    • 12.2.5. Other Indications
  • 12.3. Market Value Forecast, by Drug Type, 2017-2031
    • 12.3.1. Cholinesterase Inhibitors
    • 12.3.2. NMDA Antagonists & Combination Drugs
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Indication
    • 12.6.2. By Drug Type
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Cognitive Disorders Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Indication, 2017-2031
    • 13.2.1. Lewy Body Dementia
    • 13.2.2. Parkinson's Disease Dementia
    • 13.2.3. Alzheimer's Disease
    • 13.2.4. Vascular Dementia
    • 13.2.5. Other Indications
  • 13.3. Market Value Forecast, by Drug Type, 2017-2031
    • 13.3.1. Cholinesterase Inhibitors
    • 13.3.2. NMDA Antagonists & Combination Drugs
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Indication
    • 13.6.2. By Drug Type
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Cognitive Disorders Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Indication, 2017-2031
    • 14.2.1. Lewy Body Dementia
    • 14.2.2. Parkinson's Disease Dementia
    • 14.2.3. Alzheimer's Disease
    • 14.2.4. Vascular Dementia
    • 14.2.5. Other Indications
  • 14.3. Market Value Forecast, by Drug Type, 2017-2031
    • 14.3.1. Cholinesterase Inhibitors
    • 14.3.2. NMDA Antagonists & Combination Drugs
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Indication
    • 14.6.2. By Drug Type
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Eisai Co., Ltd.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Novartis AG (Knight Therapeutics)
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Biogen, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Takeda Pharmaceutical Company Limited
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Dr. Reddy's Laboratories Ltd.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Adamas Pharmaceuticals, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Allergan plc
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Actavis plc
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. H. Lundbeck A/S
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 03: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 06: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Indication, 2017-2031
  • Table 07: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Distribution Channel, 2017-2031
  • Table 08: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 10: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Indication, 2017-2031
  • Table 11: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Distribution Channel, 2017-2031
  • Table 12: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 18: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Indication, 2017-2031
  • Table 19: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, By Distribution Channel, 2017-2031
  • Table 20: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 22: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 23: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 02: Global Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 03: Global Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
  • Figure 04: Global Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023-2031
  • Figure 05: Global Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
  • Figure 06: Global Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023-2031
  • Figure 07: Global Cognitive Disorders Treatment Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 08: Global Cognitive Disorders Treatment Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 09: North America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: North America Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 11: North America Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 12: North America Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
  • Figure 13: North America Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023-2031
  • Figure 14: North America Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
  • Figure 15: North America Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023-2031
  • Figure 16: North America Cognitive Disorders Treatment Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 17: North America Cognitive Disorders Treatment Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 18: Europe Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 19: Europe Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 20: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 21: Europe Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
  • Figure 22: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023-2031
  • Figure 23: Europe Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
  • Figure 24: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023-2031
  • Figure 25: Europe Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Europe Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Asia Pacific Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 29: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 30: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 31: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 32: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
  • Figure 33: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023-2031
  • Figure 34: Asia Pacific Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Asia Pacific Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Latin America Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Latin America Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 38: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 39: Latin America Cognitive Disorders Treatment Market Value Share Analysis, By Indication, 2022 and 2031
  • Figure 40: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, By Indication, 2023-2031
  • Figure 41: Latin America Cognitive Disorders Treatment Market Value Share Analysis, By Distribution Channel, 2022 and 2031
  • Figure 42: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, By Distribution Channel, 2023-2031
  • Figure 43: Latin America Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 44: Latin America Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 45: Middle East & Africa Cognitive Disorders Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 47: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 48: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 49: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 50: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 52: Middle East & Africa Cognitive Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 53: Middle East & Africa Cognitive Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 54: Global Cognitive Disorders Treatment Market Share Analysis, by Company, 2022